<DOC>
	<DOCNO>NCT01797185</DOCNO>
	<brief_summary>Open-label , safety study SPARC1104 subject spasticity due multiple sclerosis</brief_summary>
	<brief_title>An Open Label Safety Study Safety Of SPARC1104</brief_title>
	<detailed_description>Safety study SPARC1104</detailed_description>
	<mesh_term>Muscle Spasticity</mesh_term>
	<criteria>Willingness participate give write informed consent Men woman â‰¥ 18 year age Sexually active woman child bear potential practice acceptable method birth control duration trial judge investigator . Examples acceptable contraception : condom , foam , jelly , diaphragm , intrauterine device , oral longacting injected contraceptive , bilateral tubal ligation , bilateral oophorectomy , hysterectomy , partner incapable initiate conception . The practice contraception must start least 3 month prior trial entry . If female , negative pregnancy test result Screening Diagnosed MS known history spasticity Meet one follow criterion Subjects complete doubleblind randomized withdrawal phase ( Part 3 ) trial CLR_09_21 major protocol violation Subjects newly diagnose spasticity due MS history treatment use antispasticity medication , , history spasticity due MS previous exposure baclofen treatment Subjects receive stable baclofen IR dose ( ie , dose 10 mg 80 mg daily , start least 30 day prior enrollment )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>baclofen , spasticity</keyword>
</DOC>